Glucose-dependent Insulinotropic Polypeptide (GIP) and Lipid Metabolism
NCT ID: NCT00999271
Last Updated: 2009-10-21
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
30 participants
OBSERVATIONAL
2008-08-31
2009-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Physiology of GIP(1-30)NH2 in Humans
NCT04792762
GIP and GLP-1 on Gastric Emptying, Appetite and Insulin-glucose
NCT01079624
Delinieation of GIP's Effects During a Meal in Humans Using GIP Receptor Antagonisation (GA-4)
NCT03013296
GIP Receptor Antagonist Studies in Humans
NCT02747472
The Influence Of GIP (Glucose-Dependent Insulinotropic Polypeptide) Infusion On Human Adipose Tissue: An In Vivo Study
NCT00809029
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Healthy subjects
30 healthy subjects without family history of diabetes or gastrointestinal disease, a normal oral glucose tolerance test (OGTT) and no intake of medicine
Incretin hormone - Glucose-dependent insulinotropic polypeptide (GIP)
two different dosages:
* 0.8 pmol/kg/min
* 1.5 pmol/kg/min for 300 minutes
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Incretin hormone - Glucose-dependent insulinotropic polypeptide (GIP)
two different dosages:
* 0.8 pmol/kg/min
* 1.5 pmol/kg/min for 300 minutes
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Caucasians over the age of 18 years
* Normal 75 g oral glucose tolerance test (OGTT)
* Normal blood haemoglobin concentration
* Normal plasma lipid profile
Exclusion Criteria
18 Years
50 Years
MALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hvidovre University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
University of Copenhagen
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hvidovre Hospital
Hvidovre, , Denmark
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HD-2009-0025
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.